Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + erlotinib
- Development stage
- Phase 1
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Atezolizumab + erlotinib is a combination therapy that pairs a PD-L1 inhibitor (atezolizumab) with an EGFR tyrosine kinase inhibitor (erlotinib). This combination was developed to enhance antitumor immunity and extend efficacy in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). Atezolizumab works by blocking PD-L1, preventing its interaction with PD-1 and B7-1 receptors, thereby removing inhibition of immune responses. Erlotinib blocks the epidermal growth factor receptor (EGFR), inhibiting the tyrosine kinase enzyme and interrupting signaling pathways that drive cancer progression.
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on atezolizumab + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + erlotinib.